2026-05-22T11:08:17Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/187362024-02-27T15:10:15Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud author Kardas, Przemysław author Bago, Martina author Barnestein-Fonseca, Pilar author Garuolienė, Kristina author Granas, Anne Gerd author Gregório, João author Hadžiabdić, Maja Ortner author Kostalova, Barbora author Leiva-Fernández, Francisca author Lewek, Pawel author Mala-Ladova, Katerina author Schneider, Marie Paule author van Boven, Job F M author Volmer, Daisy author Ziampara, Ioli author Ágh, Tamás 2024-02-27T15:10:15Z 2024-02-27T15:10:15Z 2022-08-11 10.3389/fphar.2022.944829 1663-9812 Frontiers in pharmacology http://hdl.handle.net/10668/20710 36034792 http://hdl.handle.net/20.500.12105/18736 Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Methods: Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Results: Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors (n = 6), nurses (n = 6), or pharmacists (n = 3). The most common types of MAEIs were education (n = 6), medication regimen management (n = 5), and adherence monitoring feedback (n = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, i.e., implementation and persistence. Conclusion: Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement. eng Europe drugs healthcare systems interventions medication adherence non-adherence persistence reimbursement Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges. research article